IL6 and inflammatory bowel disease: In the context of inflammatory bowel disease (IBD), ASX supplementation has been shown to reduce colonic inflammation by downregulating cytokines such as TNF-α, IL-1β, and IL-6, while enhancing endogenous antioxidant defenses including superoxide dismutase and glutathione peroxidase.